search
Back to results

Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses (LIPSIASTRATEGY)

Primary Purpose

Coronary Artery Disease, Coronary Artery Stenoses

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
measurement of FFR
measurement of Pd/Pa
Sponsored by
Helios Health Institute GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age >18 years
  • Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
  • Eligible for coronary angiography and/or PCI
  • Coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-80% diameter stenosis).
  • Stable angina or acute coronary syndrome (non-culprit vessels only and outside of primary intervention during acute STEMI or NSTE-ACS)
  • Participation in another interventional study

Exclusion Criteria:

  • Previous CABG with patent grafts to the interrogated vessel
  • Tandem stenoses separated by more than 10 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis)
  • Total coronary occlusions
  • Hemodynamic instability (Killip class III-IV)
  • Heavily calcified or tortuous vessels
  • Terminal disease with life expectancy of less than 12 months
  • STEMI within 48 hours of procedure
  • Severe valvular heart disease
  • ACS patients with difficulty in assessing which the culprit lesion is
  • Significant contraindication to adenosine administration (e.g. Asthma bronchiale)
  • Pregnancy

Sites / Locations

  • Heart Center Dresden - University ClinicRecruiting
  • University Clinic ErlangenRecruiting
  • Universitätsklinikum EssenRecruiting
  • University Clinic Giessen and MarburgRecruiting
  • Herzzentrum LeipzigRecruiting
  • University Clinic LeipzigRecruiting
  • Klinikum der Stadt LudwigshafenRecruiting
  • Lukaskrankenhaus NeussRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Pd/Pa guided Therapy

FFR guided therapy

Arm Description

use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses

use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses

Outcomes

Primary Outcome Measures

Major Adverse Cardiac Event (MACE) rate
composite of cardiac death, non-fatal myocardial infarction or unplanned revascularization

Secondary Outcome Measures

MACE during long-term follow-up
Each component of the primary endpoint assessed by structured telephone interview and verification by hospital reports
Repeat revascularization (PCI or CABG) assessed by structured telephone interview and verification by hospital reports in case of event
All-cause mortality
Cross-over rate from the one strategy to the other
Number of analyzable lesions in both treatment arms

Full Information

First Posted
April 6, 2018
Last Updated
September 25, 2023
Sponsor
Helios Health Institute GmbH
Collaborators
Heart Center Leipzig - University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03497637
Brief Title
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
Acronym
LIPSIASTRATEGY
Official Title
Comparison of Non-Invasive Vessel Fractional Flow Reserve Calculated From Angiographic Images Versus Fractional Flow Reserve in Patients With Intermediate Coronary Artery Stenoses
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 23, 2020 (Actual)
Primary Completion Date
May 1, 2026 (Anticipated)
Study Completion Date
November 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Helios Health Institute GmbH
Collaborators
Heart Center Leipzig - University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether vFFR is non-inferior to FFR in assessment of intermediate coronary stenosis in terms of the occurrence of MACE during 12 months after randomization.
Detailed Description
Coronary angiography is insensitive to assess the physiologic significance of a coronary stenosis. Therefore, clinical guidelines support the use of pressure-derived fractional flow reserve (FFR) to assess the hemodynamic significance of coronary stenosis. Nevertheless, the penetration of FFR in clinical routine continues to be limited by its requirement for pharmacological vasodilation, prolonged procedure time and adverse systemic effects from adenosine. Vessel-FFR (vFFR) is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. The vFFR values at each point along the vessel are color-coded and superimposed on the 3D epicardial model and cut-off values of ≤0.80 identical to standard invasive FFR apply. These developments may translate towards more physiology guided intervention bearing the potential to improve clinical outcomes in patients with stable CAD. The ability to derive FFR values from routinely performed coronary angiograms, without the practical drawbacks that limit invasive techniques, could have an important impact on daily clinical practice. To date no randomized outcome-based clinical trial has compared an image-based FFR methodology with standard invasive FFR in terms of subsequent clinical outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Coronary Artery Stenoses

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1926 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pd/Pa guided Therapy
Arm Type
Active Comparator
Arm Description
use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
Arm Title
FFR guided therapy
Arm Type
Active Comparator
Arm Description
use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
Intervention Type
Diagnostic Test
Intervention Name(s)
measurement of FFR
Intervention Description
use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
Intervention Type
Diagnostic Test
Intervention Name(s)
measurement of Pd/Pa
Intervention Description
use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
Primary Outcome Measure Information:
Title
Major Adverse Cardiac Event (MACE) rate
Description
composite of cardiac death, non-fatal myocardial infarction or unplanned revascularization
Time Frame
1 year
Secondary Outcome Measure Information:
Title
MACE during long-term follow-up
Time Frame
2 and 5 years
Title
Each component of the primary endpoint assessed by structured telephone interview and verification by hospital reports
Time Frame
1, 2 and 5 years
Title
Repeat revascularization (PCI or CABG) assessed by structured telephone interview and verification by hospital reports in case of event
Time Frame
1, 2 and 5 years
Title
All-cause mortality
Time Frame
1, 2 and 5 years
Title
Cross-over rate from the one strategy to the other
Time Frame
at intervention
Title
Number of analyzable lesions in both treatment arms
Time Frame
at intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 years Willing to participate and able to understand, read and sign the informed consent document before the planned procedure Eligible for coronary angiography and/or PCI Coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-80% diameter stenosis). Stable angina or acute coronary syndrome (non-culprit vessels only and outside of primary intervention during acute STEMI or NSTE-ACS) Participation in another interventional study Exclusion Criteria: Previous CABG with patent grafts to the interrogated vessel Tandem stenoses separated by more than 10 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis) Total coronary occlusions Hemodynamic instability (Killip class III-IV) Heavily calcified or tortuous vessels Terminal disease with life expectancy of less than 12 months STEMI within 48 hours of procedure Severe valvular heart disease ACS patients with difficulty in assessing which the culprit lesion is Significant contraindication to adenosine administration (e.g. Asthma bronchiale) Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Holger Thiele, MD
Phone
+49 341 865 1428
Email
holger.thiele@medizin.uni-leipzig.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Holger Thiele, MD
Organizational Affiliation
Heart Center Leipzig - University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Heart Center Dresden - University Clinic
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felix Woitek, Dr.
Facility Name
University Clinic Erlangen
City
Erlangen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luise Gaede, Dr.
Facility Name
Universitätsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tienush Rassaf, Prof. Dr.
Facility Name
University Clinic Giessen and Marburg
City
Gießen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Holger Nef, Prof.
Facility Name
Herzzentrum Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Holger Thiele, MD
Facility Name
University Clinic Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulrich Laufs, Prof.
Facility Name
Klinikum der Stadt Ludwigshafen
City
Ludwigshafen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uwe Zeymer, Prof.
Facility Name
Lukaskrankenhaus Neuss
City
Neuss
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Haude, Prof.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses

We'll reach out to this number within 24 hrs